About Us

About Array

Values 
At Array, we embrace three core values that guide our day-to-day activities:

    1. Integrity and transparency in what we do and how we do it
    2. A sense of urgency and creativity in bringing benefit to patients
    3. The knowledge to achieve our critical objectives

Array Today
Array markets in the United States BRAFTOVI (encorafenib) capsules in combination with MEKTOVI® (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation as detected by an FDA-approved test.* Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including selumetinib (partnered with AstraZeneca), larotrectinib (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797 (being developed by Yarra Therapeutics, a wholly-owned subsidiary of Array), all of which are currently in registration trials. Ganovo® (danoprevir, partnered with Roche) was recently approved in China.

*Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma.